Evelo Biosciences, Inc. Common Stock
EVLO
EVLO was delisted on the 11th of December, 2023.
66 hedge funds and large institutions have $646M invested in Evelo Biosciences, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 27 increasing their positions, 16 reducing their positions, and 8 closing their positions.
69% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 16
63% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 8
43% more call options, than puts
Call options by funds: $607K | Put options by funds: $424K
27% more capital invested
Capital invested by funds: $508M → $646M (+$138M)
6% more funds holding
Funds holding: 62 → 66 (+4)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$2.12M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.56M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$1.35M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$8.56M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$1.76M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$1.1M |
| 4 |
Millennium Management
New York
|
-$937K |
| 5 |
CCM
CAAS Capital Management
New York
|
-$883K |
EVLO Hedge Fund Activity: Q2 2021 in Review
66 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Evelo Biosciences, Inc. Common Stock (EVLO) for Q2 2021, worth a combined $646M — up 27% from $508M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new EVLO positions and 8 closed out — a net gain of 5 holders — while 27 added to existing stakes and 16 trimmed.
The largest buyer was BlackRock, adding an estimated $2.7M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $8.56M sold.
- 66 institutional investors held Evelo Biosciences, Inc. Common Stock (EVLO) as of Q2 2021, up from 62 in Q1 2021.
- Funds reported $646M of Evelo Biosciences, Inc. Common Stock stock for Q2 2021, up 27% quarter-over-quarter.
- 13 funds opened new Evelo Biosciences, Inc. Common Stock positions in Q2 2021 and 8 closed out, a net change of +5 holders.
- The largest Evelo Biosciences, Inc. Common Stock buyer in Q2 2021 was BlackRock, an estimated $2.7M added.
- The largest Evelo Biosciences, Inc. Common Stock seller in Q2 2021 was Avidity Partners Management, an estimated $8.56M sold.
Based on aggregated 13F filings for Q2 2021.